The market for initial public offerings has recently delivered some great first-day gains for investors who were able to get shares before the companies went public.That left us with 11 names. First up:CureVac, which was the screen’s best-performing IPO and had a total return of 596.75%. CureVac specializes in the messenger RNA, or mRNA, technology that is the basis of several leading Covid-19 vaccine programs. The German biotech company went public inAugust at $16 a shareand soared 249% in its
Apple gets rare sell rating as New Street downgrades and predicts nearly 30% stock decline
Apple could see a significant decline in sales of its flagship iPhone and investors should get out before the stock tumbles, according to a note from New Street Research.The tech giant reportednearly $48 billion in iPhone salesfor its fiscal second quarter, helping the company blow past analyst estimates for earnings and revenue. Several analysts have said that the iPhone 12 was part of a new supercycle for Apple.However, New Street analyst Pierre Ferragu downgraded the stock to sell from neutra